atogepant Qulipta
Selected indexed studies
- Atogepant for the Preventive Treatment of Migraine. (N Engl J Med, 2021) [PMID:34407343]
- ** (, 2023) [PMID:37934843]
- ** (, 2024) [PMID:39869732]
_Worker-drafted node — pending editorial review._
Connections
atogepant Qulipta is a side effect of
Sources
- Atogepant for the Preventive Treatment of Migraine. (2021) pubmed
- Atogepant for the preventive treatment of chronic migraine (PROGRESS): a randomised, double-blind, placebo-controlled, phase 3 trial. (2023) pubmed
- Safety and efficacy of atogepant for the preventive treatment of episodic migraine in adults for whom conventional oral preventive treatments have failed (ELEVATE): a randomised, placebo-controlled, phase 3b trial. (2024) pubmed
- Atogepant: First Approval. (2022) pubmed
- PMID:37934843 (2023) pubmed
- PMID:39869732 (2024) pubmed
- PMID:39236203 (2024) pubmed
- Atogepant (Qulipta) for migraine prevention. (2021) pubmed
- Atogepant (Qulipta®) for migraine prevention. (2022) pubmed
- PMID:37797113 (2023) pubmed